Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
about
Neurophysiological basis of rapid eye movement sleep behavior disorder: informing future drug developmentFunctional neuroimaging in Parkinson's diseaseManganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primatesThe effect of Parkinson's disease on interference control during action selection.Neuroimaging in Parkinson disease: from research setting to clinical practice.Human gene therapy and imaging in neurological diseases.Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.Parkinson subtypes progress differently in clinical course and imaging patternImaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's diseaseThe role of molecular imaging in the diagnosis and management of neuropsychiatric disorders.Do dopamine agonists or levodopa modify Parkinson's disease progression?Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeuticsA within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.Aberrant functional connectivity within the basal ganglia of patients with Parkinson's diseaseTemporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's diseaseFunctional imaging in Parkinson's disease and dementia with Lewy bodies.Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.Premotor Parkinson's disease: concepts and definitionsPositron emission tomography and single-photon emission computed tomography in central nervous system drug development.Neural correlates underlying micrographia in Parkinson's disease.Putaminal Diffusivity Correlates With Disease Progression in Parkinson's Disease: Prospective 6-Year StudyMolecular imaging in hereditary forms of parkinsonism.Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.Molecular imaging as a guide for the treatment of central nervous system disordersThe search for biomarkers in Parkinson's disease: a critical review.PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.Development of Parkinson's disease biomarkers.PET/CT in diagnosis of movement disorders.Functional neuroimaging in Parkinson's disease.The role of the putamen in language: a meta-analytic connectivity modeling study.New insights on the mitochondrial proteome plasticity in Parkinson's disease.Position Emission Tomography/Single-Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease.A novel adaptive discrete cosine transform-domain filter for gap-inpainting of high resolution PET scanners.(18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparisonImproved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT.Spatial remapping of cortico-striatal connectivity in Parkinson's disease.Discrimination and categorization of emotional facial expressions and faces in Parkinson's disease.Effect of tetrabenazine on the striatal uptake of exogenous L-DOPA in vivo: a PET study in young and aged rhesus monkeys.
P2860
Q26749275-3620FA87-7594-4491-B7A5-45A818452A20Q27013767-6D0BAD47-D182-489F-9AE0-2276610F2796Q28384717-30FE8E94-384F-4C67-9C0C-8F1B3288B929Q30371505-1DED1B20-563F-4414-B107-62A57B60686CQ30868628-B5BD05E5-C448-4295-AE97-3E2F6DF4F630Q31023442-E13623FA-BBFC-4B21-8A6C-1E8CF85A1BEFQ34416128-718666A7-C5CB-4F9E-B136-456917F38242Q34442161-AA33D7F0-C49A-4494-8E64-539850CFA8F6Q34554452-1CCC37B0-3801-48F9-B9D5-0441FDC50E07Q34825634-034A051D-0856-4FBC-9A7E-237FA46A3312Q34827117-EFAA5FF5-5A1B-4FA4-9984-75AE096A46FBQ34897526-AE5BF8B0-CC82-45B0-A533-4002438004B8Q35015794-2A0CFFE4-BCE2-421D-B3FF-9D1F12BAA86CQ35649302-778C57B1-ECFB-41E7-8BC7-2F4084FB25CEQ35752869-A145D61F-2D31-49FE-8E40-EE1ED655ED6AQ35759065-8D6AC42B-E910-40D5-850D-C64219F2A979Q35846770-28AFC1AF-9525-4EE2-B800-E6BF2CAA4C47Q35863417-5CC3C5C7-54DE-4C6A-A26D-8475E60CBABFQ35910290-8175B49B-2289-4413-A0E2-08E3F353143CQ35910731-1DC8F00B-D045-4948-98C6-6D121272D9B6Q36129732-EF1994B1-FE37-4DD4-9A39-866E92C98CA0Q36481742-9A31E555-4094-47A0-8B88-2D1E3B601232Q36580852-03823637-903E-4057-B7FC-50B1A036CA5DQ36771898-45FFE483-6745-44B4-8C9F-D285E1F6A795Q37076753-67010278-05DA-4981-95A8-46786FDEFB03Q37262953-BCEEE2F5-6B1E-4B13-BF67-1670CC315E36Q37352054-D0371C31-66E0-4779-BDD0-BB9AFEB3462EQ37606115-71E35C33-6D01-48A2-8A44-25F8225C2BA2Q37810992-4870B007-E169-4704-A492-9E69D8DAF37CQ37896142-A43ECCD8-597F-4CB0-B1D1-33FF03AF0270Q38088371-ED09EC05-EDF4-4065-A3C4-F0737903421DQ38375992-81818902-3DF4-42C9-B0B6-8302C02F8BF6Q38452561-26FA56EF-8F8E-4D5F-8553-AB87E34653EDQ38699508-C3006054-5B35-43AE-9F6D-94367E23CDFCQ40212014-E913B444-E057-4C03-A647-F563D27E64E0Q41627302-85D7A9D3-B610-4620-99A4-C3805D61C6C2Q42470263-507C9B43-D886-4CFC-93A2-DCF02AD72104Q43285295-55D9E784-4017-435E-AC2D-D2C2BD67524EQ43773609-80ADEEFC-1385-4700-BB8E-D97E7C73D904Q43976825-BCFC04B2-E251-4CB5-961F-320627BB8EC1
P2860
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
@en
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
@nl
type
label
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
@en
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
@nl
prefLabel
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
@en
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
@nl
P2093
P2860
P356
P1433
P1476
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
@en
P2093
Haaparanta M
Ruottinen HM
Sonninen P
P2860
P304
P356
10.1002/MDS.1139
P407
P577
2001-07-01T00:00:00Z